Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Antisense Pharma Changes Name to Isarna Therapeutics

Published: Monday, September 30, 2013
Last Updated: Monday, September 30, 2013
Bookmark and Share
Development efforts focused on next generation oligonucleotides to treat cancer capitalizing on long-standing experience in TGF-ß.

Antisense Pharma GmbH has changed its name to Isarna Therapeutics GmbH and centralized all of its activities to a single location in Munich, the company announced today at the Sachs 13th Annual Biotech in Europe Investor Forum held in Zurich, Switzerland. The company’s new website is

“The name change to Isarna Therapeutics illustrates our new company dynamics combined with our continued leadership in the TGF-β pathway,” explained Dr. Philippe Calais, CEO of Isarna Therapeutics.  “We are currently extending our pipeline to include next-generation oligonucleotides to treat cancer and expect several key near-term events that highlight this momentum.”

Isarna Therapeutics is committed to rapidly advancing a pipeline of next generation oligonucleotides (NGOs) targeting the various isoforms of TGF-β, a family of cytokine proteins that plays a significant role in cancer’s ability to escape immune system detection and promote tumor growth. Based on its unique deciphering of the TGF-β biology, the company has to date amassed an unmatched expertise in discovery and clinical development of oligonucleotides antagonists of the various TGF-β isoforms.  Much of this knowledge is the result of developing its first-generation compound trabedersen for several cancer indications and up to a Phase III clinical trial. The further development of that compound is focused on a Responder Patient Profiling Program (RPPP), aimed at assessing the genetic profile and responder biomarkers of patients suffering from cancer to establish correlations between tumor biology and response to anti-TGF-β oligonucleotides. This unique proprietary program will allow Isarna Therapeutics to select the right patients who will be best suited for treatment not only by trabedersen but also by any of the next generation of TGF-β inhibitors entering clinical development.

“Our goal as a company is to solidify our strengths in the TGF-β isoform family and remain a lean and focused organization capable of rapidly advancing compounds into mid-stage clinical development,” added Dr. Calais.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Antisense Pharma Receives FDA Orphan Drug Designation for Trabedersen
TGF-ß2 inhibitor has gained market exclusivity in the USA for a third aggressive cancer indication.
Friday, October 05, 2012
Antisense Pharma Presents Trabedersen Phase I/II Complete Data at ASCO
Trabedersen demonstrated excellent safety combined with encouraging survival in patients with advanced pancreatic cancer and malignant melanoma.
Tuesday, June 05, 2012
Antisense Pharma Internationalizes Management Board
Dr. Philippe Calais appointed Chief Executive Officer.
Tuesday, May 15, 2012
Antisense Pharma Completes Round of Financing Worth Approximately 8 Million Euro
Effective July, 2011, Antisense Pharma’s founder and CEO, Dr. Karl-Hermann Schlingensiepen, will now be a member of the supervisory board and will focus on the company’s strategy as a consultant.
Thursday, July 07, 2011
Antisense Pharma Receives Approval for Clinical Studies in South Korea and Taiwan in Malignant Brain Tumors
With this approval, the Southeast Asian health agencies KFDA and TFDA have paved the way for the implementation of the pivotal Phase III study SAPPHIRE with the TGF-ß2 inhibitor trabedersen.
Friday, February 18, 2011
Antisense Pharma’s Trabedersen in Malignant Brain Tumors: Phase IIb Data Published in Neuro-Oncology
The investigated drug trabedersen is designed to selectively downregulate the production of TGF-ß2 at the translational level.
Wednesday, November 03, 2010
Antisense Pharma’s Trabedersen in Malignant Brain Tumors: Phase IIb Data Published in Neuro-Oncology
Antisense Pharma have announced that their international, randomized and active-controlled Phase IIb study G004-AP 12009, has been published in the official journal of the American Society for Neuro-Oncology (SNO).
Tuesday, November 02, 2010
Antisense Pharma Obtains IND for Clinical Studies in the USA
The American Department of Health, the FDA, agrees to the use of trabedersen for high-grade glioma.
Tuesday, August 03, 2010
Scientific News
Lung Repair and Regeneration Gene Discovered
New role for hedgehog gene offers better understanding of lung disease.
How Cell Growth Triggers Cell Division
Researchers in Jan Skotheim's lab have discovered a previously unknown mechanism that controls how large cells grow, an insight that could one day provide insight into attacking diseases such as cancer.
Microbe Sleuth
Tanja Bosak examines how life and the Earth evolved in tandem during their early history together.
3 Ways Viruses Have Changed Science for the Better
Viruses are really good at what they do, and we’ve been able to harness their skills to learn about – and potentially improve – human health in several ways.
Restoring Vision with Stem Cells
Age-related macular degeneration (AMRD) could be treated by transplanting photoreceptors produced by the directed differentiation of stem cells, thanks to findings published today by Professor Gilbert Bernier of the University of Montreal and its affiliated Maisonneuve-Rosemont Hospital.
The Age of Humans Controlling Microbes
Engineered bacteria could soon be used to detect environmental toxins, treat diseases, and sustainably produce chemicals and fuels.
Mixed Up Cell Transportation Key Piece of ALS and Dementia Puzzle
Researchers from the University of Toronto are one step closer to solving this incredibly complex puzzle, offering hope for treatment.
Metabolomic Platform Reveals Fundamental Flaw in Common Lab Technology
A new study led by scientists at The Scripps Research Institute (TSRI) shows that a technology used in thousands of laboratories, called gas chromatography mass spectrometry (GC-MS), fundamentally alters the samples it analyzes.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
New Gene Therapy for Vision Loss From a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos